Relay Therapeutics, Inc.(RLAY)

Description: Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its product candidates include RLY-1971, an oral small molecule inhibitor of the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 (SHP2) that is in Phase 1 dose escalation studies in patients with advanced or metastatic solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2) for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.

---

Keywords: Solid Tumors Drug Discovery Enzymes Tyrosine Kinase Precision Medicine Advanced Solid Tumors Tyrosine Kinase Receptors Metastatic Solid Tumors Fibroblast Growth Factor Fibroblast Growth Factor Receptor Proto Oncogene Tyrosine Protein Kinase Src Ptpn11

---

Home Page: www.relaytx.com

RLAY Technical Analysis

399 Binney Street
Cambridge, MA 02139
United States
Phone: 617 370 8837

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)